Bio Green Med Solution, Inc. Files 8-K on Asset Deal
Ticker: BGMSP · Form: 8-K · Filed: Oct 7, 2025 · CIK: 1130166
| Field | Detail |
|---|---|
| Company | Bio Green Med Solution, INC. (BGMSP) |
| Form Type | 8-K |
| Filed Date | Oct 7, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $300,000, $170,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, acquisition, disposition, exhibits
TL;DR
BGMS filed an 8-K for a material agreement and asset deal on 10/6.
AI Summary
Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc. and Xcyte Therapies Inc.) filed an 8-K on October 7, 2025, reporting on the entry into a material definitive agreement and the completion of an acquisition or disposition of assets as of October 6, 2025. The filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity, including a material definitive agreement and asset transaction, which could impact the company's structure and future operations.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and asset transaction, which can introduce significant changes and associated risks for the company.
Key Players & Entities
- Bio Green Med Solution, Inc. (company) — Registrant
- Cyclacel Pharmaceuticals, Inc. (company) — Former Company Name
- XCYTE THERAPIES INC (company) — Former Company Name
- October 6, 2025 (date) — Date of earliest event reported
- October 7, 2025 (date) — Date of Report
FAQ
What type of material definitive agreement did Bio Green Med Solution, Inc. enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into as of October 6, 2025.
What was the nature of the asset acquisition or disposition reported?
The filing indicates the completion of an acquisition or disposition of assets as of October 6, 2025, but does not provide specific details about the assets involved.
When was the report filed with the SEC?
The report was filed on October 7, 2025.
What are the former names of Bio Green Med Solution, Inc. mentioned in the filing?
The former names mentioned are Cyclacel Pharmaceuticals, Inc. and XCYTE THERAPIES INC.
What is the Standard Industrial Classification (SIC) code for Bio Green Med Solution, Inc.?
The SIC code listed is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 666 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2025-10-07 09:00:34
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BGMS The Nasdaq Capital M
- $300,000 — cies ("Plogo"), for a purchase price of $300,000, plus a further potential Milestone (as
- $170,000 — s defined in the Purchase Agreement) of $170,000. The Purchase Agreement contains cust
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex2-1.htm (EX-2.1) — 308KB
- form8-k_001.jpg (GRAPHIC) — 13KB
- 0001493152-25-017223.txt ( ) — 643KB
- bgms-20251006.xsd (EX-101.SCH) — 4KB
- bgms-20251006_def.xml (EX-101.DEF) — 26KB
- bgms-20251006_lab.xml (EX-101.LAB) — 36KB
- bgms-20251006_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: October 7, 2025 Bio Green Med Solution, Inc. By: /s/ Datuk Dr. Doris Wong Sing Ee Name: Datuk Dr. Doris Wong Sing Ee Title: Chief Executive Officer and Executive Director